Stockscreener 앱 받기
2.11
1.20%
0.02
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Allogene at H.C. Wainwright conference: cema-cel data lift strategy By Investing.com - Investing.com Canada
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Allogene Therapeutics (ALLO) Stock Gets Fair Value Boost After Split Analyst Revisions - Yahoo Finance
Price to earnings forward of Allogene Therapeutics, Inc. – NASDAQ:ALLO - TradingView
Enterprise value to EBITDA forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Enterprise value to revenue forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Price to book forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
ALLO Stock Hits 2-Year Highs – Analyst Calls Allogene’s Phase 2 Trial Data To Treat Lymphoma A ‘Home Run’ - Stocktwits
Enterprise value to EBIT forward of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALLO) - TradingView
Why is Allogene Therapeutics (ALLO) down 12.2% since last earnings report? - MSN
ALLO Forecast — Price Target — Prediction for 2027 - TradingView
Allogene Therapeutics unveils strategy to overcome autologous CAR T cell therapy limitations - Traders Union
Allogene Therapeutics (ALLO) Short Interest & Short Float | Updated Jun 2026 $ALLO - MarketBeat
Recent pharma exec shake-ups signal strategic shifts - Pharma Voice
Form 4 Allogene Therapeutics Inc For: 23 June By Investing.com - Investing.com Nigeria
Allogene (ALLO) director Kazam converts 47,700 RSUs and receives 95,400-unit equity grant - Stock Titan
Allogene Therapeutics (NASDAQ: ALLO) grants director 95,400 RSUs - Stock Titan
Allogene Therapeutics (ALLO) director receives 144,400 stock options grant - Stock Titan
Allogene Therapeutics (ALLO) director receives 95,400 RSU equity award - Stock Titan
Allogene (ALLO) director Owen Witte awarded 95,400 RSUs with deferred delivery - Stock Titan
[Form 4] Allogene Therapeutics, Inc. Insider Trading Activity - Stock Titan
Allogene (ALLO) director awarded 95,400 RSUs with deferred share delivery - Stock Titan
Form 424B5 Allogene Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Allogene Therapeutics (NASDAQ: ALLO) doubles authorized shares and files $135M ATM plan - Stock Titan
Allogene (NASDAQ: ALLO) launches $135M ATM program with TD Cowen at $2.00 ref - Stock Titan
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
ALLO: All proposals, including director elections and share increase, were approved without contest - TradingView
ALLO: All proposals passed, including director elections and share authorization increase - TradingView
Allogene Therapeutics Inc (ALLO) Institutional Confidence - TradingKey
Allogene Therapeutics Inc (ALLO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Allogene Therapeutics Inc (ALLO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Allogene Therapeutics Inc (ALLO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Allogene Therapeutics (ALLO) Is Expanding Its Off-the-Shelf CAR T Platform Across Cancer and Autoimmune Disease - Insider Monkey
Allogene Therapeutics Inc (ALLO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Allogene Therapeutics Inc (ALLO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Allogene Therapeutics Inc (ALLO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Allogene Therapeutics Stock Surges on Optimistic Trial Results and Price Target Increase - timothysykes.com
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report? - Yahoo Finance
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Allogene Therapeutics, Inc. (ALLO) A Top Penny Stock to Buy on Robust CAR T-Cell Portfolio - Insider Monkey
A pioneering founder is stepping down as CEO of his Bay Area company ahead of a major test - The Business Journals
1.16%
0.48%
자본화:
|
볼륨(24시간):